Long-term benefits of preventing venous thromboembolic events

Current Medical Research and Opinion

Volumn 28, Issue 6, 2012, Pages 877-889

  Cohen, Alexander T ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation; Pharmacoeconomics; Recurrence; Rivaroxaban; Secondary prevention; Venous thromboembolism

Indexed keywords

APIXABAN; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; HEALTH CARE COST; HEART PALPITATION; HUMAN; LUNG EMBOLISM; MEDLINE; MORTALITY; PATIENT CARE; POSTTHROMBOSIS SYNDROME; REVIEW; RISK FACTOR; THORAX PAIN; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE III AS TOPIC; FOLLOW-UP STUDIES; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDINES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; THIAZOLES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 84862550135     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.688737     Document Type: Review

References (64)

1. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-64.
2. Heit JA, Cohen AT, Anderson FA, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) 2005;106. Abstract 910.
3. The Prevention of Venous Thromboembolism in Hospitalised Patients; Second Report of Session 2004-05. House of Commons Health Committee, 2005. Available at: http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/99. pdf [Last accessed 9 February 2012].
4. Spyropoulos AC, Hurley JS, Ciesla GN, et al. Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin. Chest 2002;122:108-14.
5. Spyropoulos A, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86.
6. Sullivan SD, Kahn SR, Davidson BL, et al. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics 2003;21:477-96.
7. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-94.
8. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 2008;133:454S-545S.
9. Schellong SM, Bounameaux H, Buller H. Venous thromboembolism. In: Camm AJ, Lüscher TF, Serruys PW, eds. The ESC Textbook of Cardiovascular Medicine, 2nd edn. Oxford: Oxford University Press, 2009:1335-58.
10. Caprini JA, Tapson VF, Hyers TM, et al. Treatment of venous thromboembo-lism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs. J Vasc Surg 2005;42:726-33.
11. Arepally G, Bauer KA, Bhatt DL, et al. The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis: a survey of current knowledge and practice supporting the need for clinical education. Crit Pathw Cardiol 2010;9:41-8.
12. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.
13. Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199-205.
14. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133:141-59S.
15. Rajgopal R, Bear M, Butcher MK, et al. The effects of heparin and low molecular weight heparins on bone. Thromb Res 2008;122:293-8.
16. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 2008;133:160S-98S.
17. Oake N, Fergusson DA, Forster AJ, et al. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 2007;176:1589-94.
18. Rose AJ, Ozonoff A, Grant RW, et al. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009;2:591-7.
19. Girard P, Musset D, Parent F, et al. High prevalence of detectable deep venous thrombosis in patients with acute pulmonary embolism. Chest 1999;116:903-8.
20. Goldhaber SZ. Pulmonary embolism. N Engl J Med 1998;339:93-104.
21. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30.
22. Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy 2009;29:943-53.
23. Baglin T. What happens after venous thromboembolism? J Thromb Haemost 2009;7(Suppl 1):287-90.
24. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769-74.
25. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-60.
26. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation 2010;121:1630-6.
27. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous throm-boembolism. N Engl J Med 2010;363:2499-510.
28. Schulman S, Baanstra D, Eriksson H, et al. Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011;9(Suppl 2):22. Abstract O-MO-037.
29. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 2001;345:165-9.
30. Goldhaber SZ. Prevention of recurrent idiopathic venous thromboembolism. Circulation 2004;110:IV20-4.
31. Agnelli G, Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008;25:37-44.
32. Bullano MF, Willey V, Hauch O, et al. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005;11:663-73.
33. Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis 2009;28:465-76.
34. Kahn SR. Frequency and determinants of the postthrombotic syndrome after venous thromboembolism. Curr Opin Pulm Med 2006;12:299-303.
35. Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009;145:286-95.
36. Kahn SR. The post-thrombotic syndrome. Hematology Am Soc Hematol Educ Program 2010;2010:216-20.
37. Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 2004;164:17-26.
38. Kahn SR, Solymoss S, Lamping DL, et al. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. J Gen Intern Med 2000;15:425-9.
39. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008;149:698-707.
40. van Dongen CJ, Prandoni P, Frulla M, et al. Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost 2005;3:939-42.
41. Kahn SR. How I treat postthrombotic syndrome. Blood 2009;114:4624-31.
42. Stain M, Schonauer V, Minar E, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 2005;3:2671-6.
43. MacDougall DA, Feliu AL, Boccuzzi SJ, et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006;63:S5-S15.
44. Ramacciotti E, Gomes M, de Aguiar ET, et al. A cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil. Thromb Res 2006;118:699-704.
45. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64.
46. Lang I. Advances in understanding the pathogenesis of chronic thromboem-bolic pulmonary hypertension. Br J Haematol 2010;149:478-83.
47. Klok FA, Huisman MV. Epidemiology and management of chronic thrombo-embolic pulmonary hypertension. Neth J Med 2010;68:347-51.
48. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proc Am Thorac Soc 2006;3:564-7.
49. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177:1122-7.
50. Fanikos J, Piazza G, Zayaruzny M, et al. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost 2009;102:688-93.
51. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edn). Chest 2008;133:110-12S.
52. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:2276-315.
53. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
54. Bayer HealthCare AG. Xarelto (rivaroxaban) Summary of Product Characteristics. 2012. Available at: http://www.ema.europa.eu/docs/en/GB/ document/library/EPAR/-/Product/Information/human/000944/WC500057108.pdf [Last accessed 15 February 2012]
55. Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. 2011. Available at: http://www. ema.europa.eu/docs/en/GB/document/library/EPAR/-/Product/Information/human/ 000829/WC500041059.pdf [Last accessed 6 January 2012]
56. Bristol-Myers Squibb, Pfizer EEIG. Eliquis (apixaban) Summary of Product Characteristics. 2011. Available at: http://www.eliquis.com/PDF/ ELIQUIS%20%20(apixaban)%20SmPC.pdf [Last accessed 6 February 2012]
57. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
58. Schulman S, Ericsson H, Goldhaber SZ, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J Thromb Haemost 2011;9 (Suppl 2):731. Abstract O-TH-033.
59. Leo Laboratories Limited. Heparin (mucous) injection BP Summary of Product Characteristics. 2010. Available at: http://www.medicines.org.uk/EMC/ medicine/8308 [Last accessed 12 December 2011]
60. Glaxo Group Ltd. Arixtra (fondaparinux sodium 5 mg, 7.5 mg, 10mg injection) Summary of Product Characteristics. 2011. Available at: http://emc medicines.org.uk/medicine/15937 [Last accessed 12 December 2011]
61. Sanofi-Aventis. Clexane (enoxaparin sodium) Summary of Product Characteristics. 2011. Available at: http://www.sanofi-aventis.co.uk/prod-ucts/ Clexane/SPC.pdf [Last accessed 28 February 2012]
62. Sandoz Ltd. Warfarin (warfarin sodium 3 mg tablets) Summary of Product of Characteristics. 2010. Available at: http://www.drugs.com/uk/warfarin-3-mg- tablets-sandoz-ltd-spc-8827.html [Last accessed 6 March 2012]
63. Nutescu EA. Antithrombotic therapy for the treatment of venous thromboembolism. Am J Manag Care 2003;9:S103-14.
64. Schulman S, Kakkar AK, Schellong SM, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RECOVER II). Blood (ASH Annual Meeting Abstracts) 2011;118. Abstract 205.